TYRA
Tyra BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-06
Current thesis
September SURF302 data could validate dabogratinib in IR NMIBC and support a rerating, while $353.9 million of cash, equivalents, and marketable securities provides runway into the second half of 2028 [#SEC-8K-2026-08-04].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +37.3.
What can break
BEACH301 initial safety-sentinel data moved to end-Q1 2027, reducing near-term catalyst density [#SEC-8K-2026-08-04].
Momentum
38
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $45.00 · Bear $15.00
Data freshness
Prices
As of 2026-08-06
Fundamentals
As of 2026-08-06 • Vendor: Data Vendor v1
Scores
As of 2026-08-06 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-06
Investment thesis
As of 2026-08-06
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $51.09
Why
Momentum38 · Δ7d -10.2
Value41 · Δ7d -0.0
Sentiment53 · Δ7d +37.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
38
10% active weight
Current posture
7d trendSoftening
Δ7d
-10.2
Δ21d
-6.3
Value
41
40% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
53
49% active weight
Current posture
7d trendImproving
Δ7d
+37.3
Δ21d
+33.2
Why this grade
Composite grade D. Momentum 37.5 / Value 41.0 / Sentiment 52.5
Fundamentals (TTM)As of 2026-08-06
Fundamentals (TTM)
As of 2026-08-06
Market Cap
$1.61B
Beta
1.07
Shares Out
59.66M
P/E (TTM) · Derived
-13.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.88
Rev YoY
-
EPS YoY
+34.2%
Gross Margin
-
Op Margin
-
Net Debt
-$250.19M
Current Ratio
20.49
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology